（文章来源：证券日报） 证券日报网讯天益医疗11月24日在互动平台回答投资者提问时表示，截至2025年11月20日，公司股东数 为5206户。 ...

Core Viewpoint - Tianyi Medical's subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate product [2] Group 1 - The product is officially recognized as a medical device, indicating compliance with regulatory standards [2] - This approval may enhance the company's market position in the medical device sector, particularly in dialysis treatment [2]

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a Medical Device Registration Certificate from the National Medical Products Administration for its subsidiary Ningbo Tianyi Pharmaceutical Technology Co., Ltd, enhancing its product portfolio and competitive edge in the market [1]. Group 1: Product Registration Details - The registered product is a blood dialysis concentrate, classified as a Class III medical device, with a registration number of Guo Xie Zhu Zheng 2025310230, valid from November 13, 2025, to November 12, 2030 [2]. - The blood dialysis concentrate consists of two components: A concentrate (A liquid) and a connected dry powder (B powder), designed to meet the personalized treatment needs of patients with acute and chronic renal failure [2]. - A liquid is composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, while B powder contains sodium bicarbonate, utilizing acetic acid as a buffer in a medium calcium formulation [2]. Group 2: Strategic Implications - The acquisition of the medical device registration certificate extends the company's product chain and enriches its product categories, which is beneficial for enhancing the company's overall competitiveness in the healthcare market [2].

Core Viewpoint - Tianyi Medical (301097) announced that its subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate, which is intended for the treatment of acute and chronic renal failure patients undergoing hemodialysis [1] Company Summary - Tianyi Medical's subsidiary has successfully obtained regulatory approval for a new medical product, indicating progress in its product development and potential market entry [1] - The blood dialysis concentrate is specifically designed for patients with renal failure, highlighting the company's focus on addressing critical healthcare needs [1] Industry Summary - The approval of the blood dialysis concentrate aligns with the growing demand for renal care solutions, particularly in the context of increasing incidences of kidney-related diseases [1] - This development may enhance competition within the medical device sector, particularly in the field of dialysis treatment [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its blood dialysis concentrate, which includes A concentrate and B powder, enhancing its product offerings and competitive edge in the market [1] Group 1 - Tianyi Pharmaceutical, a subsidiary of Tianyi Medical, has obtained a medical device registration certificate for its blood dialysis concentrate [1] - The blood dialysis concentrate consists of A liquid, which includes sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, and dialysis water, and B powder, which contains sodium bicarbonate [1] - The combination of A liquid and B powder offers advantages of both types of concentrates, catering to personalized clinical treatment needs [1] Group 2 - The acquisition of the registration certificate extends the company's product chain and enriches its product categories [1] - This development is expected to enhance the overall competitiveness of the company in the medical device industry [1]

本次获得血液透析浓缩物为A液+B粉(联机干粉)的搭配形式，结合了血液透析浓缩液、联机干粉两种浓 缩物的优点，能更好地满足临床个性化治疗需求。该注册证的取得进一步延长了公司产品链，丰富了公 司产品类别，有利于提高公司综合竞争力。 智通财经APP讯，天益医疗(301097.SZ)发布公告，公司子公司宁波天益药业科技有限公司(简称"天益药 业")于近日收到国家药品监督管理局颁发的《医疗器械注册证》。天益药业本次获得医疗器械注册证的 血液透析浓缩物分为A浓缩液(简称A液)和联机B干粉(简称B粉)组成。A液由氯化钠、氯化钾、氯化钙、 氯化镁、冰醋酸和透析用水组成，B粉由碳酸氢钠组成，是一款冰醋酸作为缓冲剂，中钙配方的产品。 ...

证券代码： 301097 证券简称：天益医疗 公告编号：2025-063 宁波天益医疗器械股份有限公司 关于公司新产品取得产品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"公司"）子公司宁波天益药业 科技有限公司（以下简称"天益药业"）于近日收到国家药品监督管理局颁发的 《医疗器械注册证》，具体情况如下： 一、产品注册证具体情况 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 国械注准 | | 2025 | 年 11 13 | 月 | 日至 | 用于急、慢性肾功 | | 1 | 血液透析浓缩物 | 2025310230 | III | | | | | 能 衰竭 患者 的 血 | | | | | | 2030 | 年 11 月 | | 12 日 | | | | | 3 | | | | | | 液透析治疗。 | 二、对公司的影响 ...

天益医疗融资融券信息显示，融资方面，当日融资买入1680.29万元，融资偿还661.75万元，融资净买入 1018.54万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量0.0股，融券余额0.0万元。融资融 券余额6363.03万元。 近5日融资融券数据一览见下表： 证券之星消息，截至2025年11月19日收盘，天益医疗(301097)报收于58.24元，下跌5.35%，换手率 6.03%，成交量1.75万手，成交额1.02亿元。 11月19日的资金流向数据方面，主力资金净流出230.13万元，占总成交额2.25%，游资资金净流出 308.35万元，占总成交额3.01%，散户资金净流入538.48万元，占总成交额5.26%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-19 | 58.24 -5.35% | | -230.13万 | -2.25% | -308.35 ...

Core Viewpoint - Tianyi Medical (301097) experienced a decline of 5.35% in stock price, closing at 58.24 yuan, with a total market capitalization of 3.433 billion yuan as of November 19, 2025 [1] Group 1: Stock Performance - The stock opened at 60.9 yuan, reached a high of 60.91 yuan, and a low of 57.4 yuan on the same day [1] - The trading volume was 1.02 billion yuan, with a turnover rate of 6.03% [1] Group 2: Upcoming Shareholder Meeting - Tianyi Medical will hold its third temporary shareholder meeting on December 5, 2025, at 14:00, with online voting available from 9:15 to 15:00 [1] - The record date for shareholders is December 1, 2025 [1] - Agenda items include the election of non-independent and independent directors for the fourth board, amendments to the company’s articles of association and governance systems, and the addition of expected related party transactions for 2025 [1] - Certain proposals require approval from over two-thirds of the voting rights held by attending shareholders, with related shareholders abstaining from voting on relevant proposals [1]